A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly

Yuh Min Chen, Reury Perng Perng, Jen Fu Shih, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: Our aim here was to determine whether or not the addition of cisplatin into vinorelbine (V) treatment is an appropriate regimen for physically fit chemo-naïve non-small cell lung cancer (NSCLC) patients aged 70 or older. Patients and methods: Patients were randomized into vinorelbine (V) or vinorelbine plus cisplatin (VP) treatment arms. Treatment consisted of vinorelbine 25 mg/m2 intravenous infusion (IV) on days 1 and 8 every 3 weeks (V arm), or vinorelbine 22.5 mg/m2 IV on days 1 and 8 plus cisplatin 50 mg/m2 IV on day 1 every 3 weeks (VP arm). Results: Sixty-five patients were enrolled from May 2005 to December 2006, including 31 who received V treatment and 34 who received VP treatment. Objective response rates were 16.1% in V and 32.4% in VP (p = 0.009). Control rates were 51.6% in V and 82.4% in VP (p = 0.008). Myelosuppression was more common and severe in the VP arm. Any grade of anemia and neutropenia was significantly higher in the VP arm (p = 0.001 and 0.009, respectively). Fatigue sensation was more common and severe in the VP arm (p = 0.032). Median time to disease progression was 3.1 months in the V arm and 5.2 months in the VP arm (p = 0.0303). The 1-year survival rate was 50.9% in the V arm and 47.2% in the VP arm. Conclusions: Adding cisplatin to vinorelbine treatment is feasible in elderly patients, and has a better response rate and longer median time to disease progression. However, both statistically significantly higher toxicity and no survival advantage for the combination treatment was observed.

Original languageEnglish
Pages (from-to)214-219
Number of pages6
JournalLung Cancer
Volume61
Issue number2
DOIs
Publication statusPublished - Aug 2008
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Cisplatin
Intravenous Infusions
vinorelbine
Therapeutics
Disease Progression
Neutropenia
Fatigue
Anemia
Survival Rate

Keywords

  • Cisplatin
  • Elderly
  • Non-small cell lung cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology

Cite this

A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly. / Chen, Yuh Min; Perng, Reury Perng; Shih, Jen Fu; Whang-Peng, Jacqueline.

In: Lung Cancer, Vol. 61, No. 2, 08.2008, p. 214-219.

Research output: Contribution to journalArticle

@article{d60874ac112341dfa740f4741335472e,
title = "A phase II randomized study of vinorelbine alone or with cisplatin against chemo-na{\"i}ve inoperable non-small cell lung cancer in the elderly",
abstract = "Purpose: Our aim here was to determine whether or not the addition of cisplatin into vinorelbine (V) treatment is an appropriate regimen for physically fit chemo-na{\"i}ve non-small cell lung cancer (NSCLC) patients aged 70 or older. Patients and methods: Patients were randomized into vinorelbine (V) or vinorelbine plus cisplatin (VP) treatment arms. Treatment consisted of vinorelbine 25 mg/m2 intravenous infusion (IV) on days 1 and 8 every 3 weeks (V arm), or vinorelbine 22.5 mg/m2 IV on days 1 and 8 plus cisplatin 50 mg/m2 IV on day 1 every 3 weeks (VP arm). Results: Sixty-five patients were enrolled from May 2005 to December 2006, including 31 who received V treatment and 34 who received VP treatment. Objective response rates were 16.1{\%} in V and 32.4{\%} in VP (p = 0.009). Control rates were 51.6{\%} in V and 82.4{\%} in VP (p = 0.008). Myelosuppression was more common and severe in the VP arm. Any grade of anemia and neutropenia was significantly higher in the VP arm (p = 0.001 and 0.009, respectively). Fatigue sensation was more common and severe in the VP arm (p = 0.032). Median time to disease progression was 3.1 months in the V arm and 5.2 months in the VP arm (p = 0.0303). The 1-year survival rate was 50.9{\%} in the V arm and 47.2{\%} in the VP arm. Conclusions: Adding cisplatin to vinorelbine treatment is feasible in elderly patients, and has a better response rate and longer median time to disease progression. However, both statistically significantly higher toxicity and no survival advantage for the combination treatment was observed.",
keywords = "Cisplatin, Elderly, Non-small cell lung cancer, Vinorelbine",
author = "Chen, {Yuh Min} and Perng, {Reury Perng} and Shih, {Jen Fu} and Jacqueline Whang-Peng",
year = "2008",
month = "8",
doi = "10.1016/j.lungcan.2007.12.009",
language = "English",
volume = "61",
pages = "214--219",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly

AU - Chen, Yuh Min

AU - Perng, Reury Perng

AU - Shih, Jen Fu

AU - Whang-Peng, Jacqueline

PY - 2008/8

Y1 - 2008/8

N2 - Purpose: Our aim here was to determine whether or not the addition of cisplatin into vinorelbine (V) treatment is an appropriate regimen for physically fit chemo-naïve non-small cell lung cancer (NSCLC) patients aged 70 or older. Patients and methods: Patients were randomized into vinorelbine (V) or vinorelbine plus cisplatin (VP) treatment arms. Treatment consisted of vinorelbine 25 mg/m2 intravenous infusion (IV) on days 1 and 8 every 3 weeks (V arm), or vinorelbine 22.5 mg/m2 IV on days 1 and 8 plus cisplatin 50 mg/m2 IV on day 1 every 3 weeks (VP arm). Results: Sixty-five patients were enrolled from May 2005 to December 2006, including 31 who received V treatment and 34 who received VP treatment. Objective response rates were 16.1% in V and 32.4% in VP (p = 0.009). Control rates were 51.6% in V and 82.4% in VP (p = 0.008). Myelosuppression was more common and severe in the VP arm. Any grade of anemia and neutropenia was significantly higher in the VP arm (p = 0.001 and 0.009, respectively). Fatigue sensation was more common and severe in the VP arm (p = 0.032). Median time to disease progression was 3.1 months in the V arm and 5.2 months in the VP arm (p = 0.0303). The 1-year survival rate was 50.9% in the V arm and 47.2% in the VP arm. Conclusions: Adding cisplatin to vinorelbine treatment is feasible in elderly patients, and has a better response rate and longer median time to disease progression. However, both statistically significantly higher toxicity and no survival advantage for the combination treatment was observed.

AB - Purpose: Our aim here was to determine whether or not the addition of cisplatin into vinorelbine (V) treatment is an appropriate regimen for physically fit chemo-naïve non-small cell lung cancer (NSCLC) patients aged 70 or older. Patients and methods: Patients were randomized into vinorelbine (V) or vinorelbine plus cisplatin (VP) treatment arms. Treatment consisted of vinorelbine 25 mg/m2 intravenous infusion (IV) on days 1 and 8 every 3 weeks (V arm), or vinorelbine 22.5 mg/m2 IV on days 1 and 8 plus cisplatin 50 mg/m2 IV on day 1 every 3 weeks (VP arm). Results: Sixty-five patients were enrolled from May 2005 to December 2006, including 31 who received V treatment and 34 who received VP treatment. Objective response rates were 16.1% in V and 32.4% in VP (p = 0.009). Control rates were 51.6% in V and 82.4% in VP (p = 0.008). Myelosuppression was more common and severe in the VP arm. Any grade of anemia and neutropenia was significantly higher in the VP arm (p = 0.001 and 0.009, respectively). Fatigue sensation was more common and severe in the VP arm (p = 0.032). Median time to disease progression was 3.1 months in the V arm and 5.2 months in the VP arm (p = 0.0303). The 1-year survival rate was 50.9% in the V arm and 47.2% in the VP arm. Conclusions: Adding cisplatin to vinorelbine treatment is feasible in elderly patients, and has a better response rate and longer median time to disease progression. However, both statistically significantly higher toxicity and no survival advantage for the combination treatment was observed.

KW - Cisplatin

KW - Elderly

KW - Non-small cell lung cancer

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=47649090643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47649090643&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2007.12.009

DO - 10.1016/j.lungcan.2007.12.009

M3 - Article

C2 - 18243407

AN - SCOPUS:47649090643

VL - 61

SP - 214

EP - 219

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -